NTLA

17.43

2.30% -0.41

Handel nachbörslich: 17.42 -0.010 -0.06%

Intellia Therapeutics Inc (NTLA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$17.84

Offen:

$17.85

24-Stunden-Volumen:

3.17M

Relative Volume:

0.50

Marktkapitalisierung:

$2.44B

Einnahmen:

$67.67M

Nettoeinkommen (Verlust:

$-412.69M

KGV:

-4.555

EPS:

-3.8266

Netto-Cashflow:

$-395.87M

1W Leistung:

+3.01%

1M Leistung:

+28.73%

6M Leistung:

+72.06%

1J Leistung:

+70.05%

1-Tages-Spanne:

$16.85

$18.11

1-Wochen-Bereich:

$16.17

$18.48

52-Wochen-Spanne:

$7.95

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Firmenname

Intellia Therapeutics Inc

Sektor

Healthcare (1094)

Branche

Biotechnology (615)

Telefon

857-285-6200

Adresse

40 ERIE STREET, CAMBRIDGE, MA

Mitarbeiter

377

Twitter

@intelliatweets

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NTLA Intellia Therapeutics Inc	17.43	2.49B	67.67M	-412.69M	-395.87M	-3.8266
VRTX Vertex Pharmaceuticals Inc	522.25	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.23	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.94	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.59	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.46	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-02	Hochstufung	William Blair	Mkt Perform → Outperform
2025-11-12	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-11-11	Herabstufung	Evercore ISI	Outperform → In-line
2025-11-07	Herabstufung	JP Morgan	Neutral → Underweight
2025-10-28	Herabstufung	Bernstein	Outperform → Mkt Perform
2025-10-28	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-10-27	Herabstufung	Guggenheim	Buy → Neutral
2025-10-27	Herabstufung	William Blair	Outperform → Mkt Perform
2025-10-06	Hochstufung	Citizens JMP	Mkt Perform → Mkt Outperform
2025-04-21	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-03-05	Eingeleitet	H.C. Wainwright	Buy
2025-02-28	Herabstufung	Goldman	Neutral → Sell
2025-02-28	Herabstufung	JP Morgan	Overweight → Neutral
2025-01-27	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-02-23	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-04-13	Eingeleitet	Canaccord Genuity	Buy
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-03-14	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-02-01	Eingeleitet	Cantor Fitzgerald	Overweight
2023-01-24	Hochstufung	Citigroup	Sell → Neutral
2023-01-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2022-10-11	Eingeleitet	Morgan Stanley	Overweight
2022-09-21	Eingeleitet	JP Morgan	Overweight
2022-09-01	Eingeleitet	Citigroup	Sell
2022-06-17	Eingeleitet	BMO Capital Markets	Market Perform
2022-06-16	Eingeleitet	BofA Securities	Buy
2022-04-28	Eingeleitet	Credit Suisse	Outperform
2022-02-18	Eingeleitet	William Blair	Outperform
2022-02-07	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-31	Eingeleitet	Cowen	Outperform
2022-01-07	Eingeleitet	Piper Sandler	Overweight
2021-10-05	Eingeleitet	Guggenheim	Buy
2021-09-24	Eingeleitet	Stifel	Buy
2021-06-28	Bestätigt	H.C. Wainwright	Buy
2021-06-11	Eingeleitet	H.C. Wainwright	Buy
2021-05-07	Hochstufung	ROTH Capital	Neutral → Buy
2021-05-04	Eingeleitet	RBC Capital Mkts	Outperform
2021-03-04	Eingeleitet	JMP Securities	Mkt Outperform
2020-12-22	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-10-27	Eingeleitet	Truist	Buy
2020-10-14	Eingeleitet	Wells Fargo	Overweight
2020-09-18	Eingeleitet	Goldman	Buy
2020-02-28	Hochstufung	Oppenheimer	Perform → Outperform
2020-02-14	Herabstufung	Wedbush	Outperform → Neutral
2019-11-01	Hochstufung	Raymond James	Mkt Perform → Outperform
2019-07-09	Eingeleitet	Robert W. Baird	Outperform
2019-06-10	Eingeleitet	ROTH Capital	Neutral
2019-05-03	Hochstufung	Wedbush	Neutral → Outperform
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2018-11-02	Herabstufung	Wedbush	Outperform → Neutral
2018-10-29	Eingeleitet	Credit Suisse	Neutral
2018-09-21	Eingeleitet	Raymond James	Mkt Perform
2018-05-15	Hochstufung	Chardan Capital Markets	Neutral → Buy
2018-03-08	Eingeleitet	JMP Securities	Mkt Outperform
2017-11-01	Bestätigt	Jefferies	Buy
2017-06-22	Fortgesetzt	Jefferies	Buy
2017-03-28	Eingeleitet	Chardan Capital Markets	Buy
2016-08-05	Hochstufung	Jefferies	Hold → Buy

Alle ansehen

Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten

Jul 06, 2026

Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo

Jul 06, 2026

Intellia CFO Edward Dulac III sells $84,186 in stock - Investing.com

Jul 06, 2026

Intellia CFO Edward Dulac III sells $84,186 in stock By Investing.com - Investing.com Australia

Jul 06, 2026

Form 4 Intellia Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026

Intellia Therapeutics (NTLA) VP sells shares to cover RSU tax - Stock Titan

Jul 06, 2026

Intellia (NTLA) CFO’s 4,677-share sale executed under 10b5-1 plan - Stock Titan

Jul 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 06, 2026

Intellia lures 13 new employees with 53,250 stock awards - Stock Titan

Jul 06, 2026

Jul 05, 2026

More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits

Jul 05, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Jul 05, 2026

NTLAIntellia Therapeutics Inc Forecast, Target Price - Finviz

Jul 05, 2026

Jul 04, 2026

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits

Jul 04, 2026

Jul 03, 2026

Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance

Jul 03, 2026

Jul 02, 2026

Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jul 02, 2026

[144] Intellia Therapeutics, Inc. SEC Filing - Stock Titan

Jul 02, 2026

Jul 01, 2026

NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Jul 01, 2026

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% - The Globe and Mail

Jul 01, 2026

Investor Sentiment Divided in Healthcare Sector: Intellia Therap - GuruFocus

Jul 01, 2026

Intellia Therapeutics (NASDAQ:NTLA): Can Innovation Justify the Buzz? - Kalkine Media

Jul 01, 2026

Jun 28, 2026

Price to book forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Price to book forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Enterprise value to revenue forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Enterprise value to revenue forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Price to sales forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026

Enterprise value to EBIT forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Price to sales forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026

Jun 27, 2026

Liquidity Mapping Around (NTLA) Price Events - Stock Traders Daily

Jun 27, 2026

Certain Stock Options of Intellia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2026. - marketscreener.com

Jun 27, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – BOATS:NTLA - TradingView

Jun 27, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Jun 27, 2026

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics - The National Law Review

Jun 27, 2026

Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Sh - The National Law Review

Jun 27, 2026